A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)
Latest Information Update: 31 Jan 2025
At a glance
- Drugs Bevacizumab (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms DUO-O
- Sponsors AstraZeneca; AstraZeneca AB; Myriad Genetic Laboratories
Most Recent Events
- 25 Jul 2024 Planned End Date changed from 25 May 2028 to 30 Mar 2028.
- 25 Jul 2024 Planned primary completion date changed from 28 Aug 2023 to 28 Mar 2025.
- 24 Aug 2023 Planned primary completion date changed from 23 Jun 2023 to 28 Aug 2023.